MicroRNA Biomarker <i>hsa-miR-195-5p</i> for Detecting the Risk of Lung Cancer
Lei Li, Tienan Feng, Weituo Zhang, Sumeng Gao, Ruoyang Wang, Wenwen Lv, Tengteng Zhu, Herbert Yu, Biyun Qian
Abstract
Background . Lung cancer is one of the leading diagnosed cancers worldwide, and microRNAs could be used as biomarkers to diagnose lung cancer. hsa-miR-195 has been demonstrated to affect the prognosis of NSCLC (non-small-cell lung cancer) in a previous study. However, the diagnostic value of hsa-miR-195-5p in lung cancer has not been investigated. Methods . To evaluate the ability of hsa-miR-195-5p to diagnose lung cancer, we compared the expression of hsa-miR-195-5p in lung cancer patients, COPD patients, and normal controls. Receiver operating characteristic (ROC) curve analysis was performed to investigate the sensitivity and specificity of hsa-miR-195-5p . Coexpression network and pathway analysis were carried out to explore the mechanism. Results . We found that hsa-miR-195-5p had lower expression in lung cancer and COPD patients than in normal controls, and the AUC was 0.92 for diagnosing lung cancer. hsa-miR-143 correlated with hsa-miR-195-5p , and by combining these two microRNAs, the AUC was 0.97 for diagnosing lung cancer. Conclusions . hsa-miR-195-5p may act as a biomarker that contributes to the diagnosis of lung cancer and the detection of its high-risk population.